Troubled British Biotech has announced trials have shown its treatment for lung cancer is safe to give to patients.
The drug, based on artificial antibodies which mimic the body's immune system, is being given once a week to lung cancer patients at two cancer research centres in the USA.
The trial results were presented last week to an international medical conference in Germany by Dr Anthony Tolcher, of the Cancer Therapy and Research Centre in San Antonio, Texas.
Dr Tolcher said the treatment, known as BB-10901, can be safely and feasibly administered for repetitive courses at doses that produced anti-tumour activity.
A second phase I study, to assess the safety and determine the best dose for more frequent use, is being conducted in the UK.
The findings will come as a welcome boost for Cowley-based British Biotech.
Chief executive Dr Elliott Goldstein recently stepped down after failing to find a merger partner or boost the sliding share price of the company, following revelations about the effectiveness of some of the company's drugs.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article